Kinoprilam Comp: Uses, Dosage & Side Effects
A fixed-dose combination of quinapril (ACE inhibitor) and hydrochlorothiazide (thiazide diuretic) for the treatment of hypertension in adults
Kinoprilam comp is a prescription combination medicine containing two active ingredients: quinapril hydrochloride 10 mg, an angiotensin-converting enzyme (ACE) inhibitor, and hydrochlorothiazide 12.5 mg, a thiazide diuretic. This fixed-dose combination is used for the treatment of essential hypertension (high blood pressure) in adults when blood pressure is not adequately controlled by either component alone or as replacement therapy in patients already stabilized on both drugs given separately. The two active substances work through complementary mechanisms to lower blood pressure more effectively than either drug alone, while the low dose of hydrochlorothiazide helps minimize metabolic side effects.
Quick Facts: Kinoprilam Comp
Key Takeaways
- Kinoprilam comp combines quinapril (an ACE inhibitor) and hydrochlorothiazide (a thiazide diuretic) in a single tablet for convenient once-daily treatment of high blood pressure in adults.
- The combination provides additive blood pressure lowering through complementary mechanisms: quinapril relaxes blood vessels by blocking angiotensin II formation, while hydrochlorothiazide reduces blood volume through increased sodium and water excretion.
- This medication must not be used during pregnancy (especially second and third trimesters) due to the risk of serious fetal harm from the ACE inhibitor component, and is contraindicated in patients with a history of angioedema.
- The most common side effects include dry cough (from quinapril), dizziness, headache, and fatigue; regular monitoring of kidney function and electrolytes (especially potassium) is recommended.
- Important drug interactions exist with potassium supplements, potassium-sparing diuretics, lithium, NSAIDs, and other drugs affecting the renin-angiotensin system; always inform your doctor about all medications you are taking.
What Is Kinoprilam Comp and What Is It Used For?
Kinoprilam comp belongs to a class of combination antihypertensive medicines that pair an angiotensin-converting enzyme (ACE) inhibitor with a thiazide diuretic. This therapeutic combination is one of the most well-established and widely recommended strategies for treating high blood pressure, endorsed by major international guidelines including the European Society of Cardiology (ESC), the European Society of Hypertension (ESH), the American Heart Association (AHA), and the World Health Organization (WHO). The rationale for combining these two drug classes lies in their complementary mechanisms of action, which together produce a blood pressure reduction that is greater than either component alone, while also counterbalancing certain side effects of each individual drug.
The first active ingredient, quinapril hydrochloride, is a non-sulfhydryl ACE inhibitor. Quinapril itself is a prodrug that is rapidly absorbed after oral administration and then hydrolyzed in the liver to its active metabolite, quinaprilat. Quinaprilat is a potent and specific inhibitor of angiotensin-converting enzyme (ACE), also known as kininase II. ACE is a zinc metallopeptidase that catalyzes the conversion of angiotensin I (a relatively inactive decapeptide) to angiotensin II (a potent vasoconstrictor octapeptide). Angiotensin II is one of the most powerful vasoconstrictors in the body, and it also stimulates the release of aldosterone from the adrenal cortex, which promotes sodium and water retention. By inhibiting ACE, quinaprilat reduces the formation of angiotensin II, leading to decreased vasoconstriction, reduced aldosterone secretion, and consequently lower blood pressure. Additionally, ACE inhibition leads to the accumulation of bradykinin (a vasodilatory peptide that is normally degraded by ACE), which may contribute further to the antihypertensive effect but is also thought to be responsible for the characteristic dry cough side effect seen with ACE inhibitors.
The second active ingredient, hydrochlorothiazide (HCTZ), is a thiazide diuretic that has been used in clinical practice since the 1950s and remains one of the most widely prescribed antihypertensive medications worldwide. Hydrochlorothiazide works primarily in the early distal convoluted tubule of the kidney, where it inhibits the sodium-chloride symporter (NCC). This blocks the reabsorption of sodium and chloride ions from the tubular fluid back into the bloodstream, resulting in increased excretion of sodium, chloride, and water in the urine. The initial antihypertensive effect of hydrochlorothiazide is primarily due to a reduction in plasma volume and cardiac output. However, with continued use over weeks to months, the blood volume returns toward normal while peripheral vascular resistance decreases, maintaining the blood pressure reduction through a mechanism that is not yet fully understood but may involve direct vasodilatory effects on small arterioles.
The combination of quinapril and hydrochlorothiazide offers several important pharmacological advantages. First, the blood pressure lowering effects of the two drugs are additive: while quinapril reduces vascular tone through suppression of the renin-angiotensin-aldosterone system (RAAS), hydrochlorothiazide reduces blood volume. Second, hydrochlorothiazide-induced sodium depletion activates the RAAS as a compensatory mechanism, which would normally limit the diuretic's antihypertensive efficacy. The addition of quinapril blocks this compensatory RAAS activation, thereby maintaining and enhancing the blood pressure lowering effect. Third, quinapril counteracts the potassium-wasting effect of hydrochlorothiazide: because quinaprilat reduces aldosterone levels (which normally promote potassium excretion), the combination carries a lower risk of hypokalemia than hydrochlorothiazide alone. This is particularly relevant because hypokalemia can cause dangerous cardiac arrhythmias and other complications.
Kinoprilam comp is indicated for the treatment of essential hypertension in adult patients whose blood pressure is not adequately controlled by quinapril alone or hydrochlorothiazide alone, or as substitution therapy in patients who have been stabilized on both components given as separate tablets at the same doses. The use of combination therapy is consistent with current European and American hypertension guidelines, which recommend combination treatment as a first-line strategy for most patients with hypertension, particularly those with blood pressure more than 20/10 mmHg above target levels, or those with high cardiovascular risk.
International hypertension guidelines (ESC/ESH 2023, AHA/ACC 2017, WHO 2021) increasingly recommend starting with two-drug combination therapy rather than monotherapy for most patients with hypertension. This approach achieves blood pressure control more quickly, with better tolerability, and improves long-term adherence through the convenience of a single pill. The ACE inhibitor + thiazide diuretic combination is one of the preferred pairings recommended across all major guidelines.
What Should You Know Before Taking Kinoprilam Comp?
Contraindications
Kinoprilam comp must not be used in the following situations:
- Hypersensitivity: Known allergy to quinapril, hydrochlorothiazide, other ACE inhibitors, sulfonamide-derived drugs, or any of the excipients in the formulation. Hydrochlorothiazide is structurally related to sulfonamide antibiotics, and cross-sensitivity is possible in patients with sulfonamide allergy, although this is rare.
- History of angioedema: Patients who have previously experienced angioedema (sudden swelling of the face, lips, tongue, throat, or extremities) with an ACE inhibitor or without a known cause must not take Kinoprilam comp. ACE inhibitor-associated angioedema can be life-threatening if it involves the airway.
- Pregnancy (second and third trimesters): ACE inhibitors cause fetal and neonatal injury and death when administered during the second and third trimesters of pregnancy. Effects include fetal hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, oligohydramnios, and death. If pregnancy is detected, Kinoprilam comp should be stopped as soon as possible.
- Bilateral renal artery stenosis or stenosis of a single functioning kidney: ACE inhibitors can cause acute renal failure in these patients by removing the angiotensin II-mediated maintenance of glomerular filtration.
- Severe renal impairment (creatinine clearance below 30 mL/min): Hydrochlorothiazide is ineffective in patients with severe renal impairment and may worsen kidney function.
- Severe hepatic impairment: Thiazide diuretics can precipitate hepatic coma in patients with severe liver disease.
- Refractory hypokalemia, hyponatremia, hypercalcemia, or symptomatic hyperuricemia (gout): Hydrochlorothiazide can worsen these electrolyte and metabolic disturbances.
- Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (GFR below 60 mL/min/1.73 m²): Dual blockade of the RAAS increases the risk of hypotension, hyperkalemia, and renal impairment.
- Concomitant use with sacubitril/valsartan: The combination with an ACE inhibitor is contraindicated due to increased risk of angioedema. Kinoprilam comp must not be started within 36 hours of the last dose of sacubitril/valsartan.
Warnings and Precautions
ACE inhibitors, including quinapril, can cause angioedema of the face, extremities, lips, tongue, glottis, and larynx. This can occur at any time during treatment, even after years of use. If angioedema occurs, stop Kinoprilam comp immediately and seek emergency medical treatment. Angioedema involving the tongue, glottis, or larynx can be fatal. Patients of African descent are at higher risk of ACE inhibitor-induced angioedema.
Before starting and during treatment with Kinoprilam comp, the following precautions should be observed:
- Kidney function: Renal function should be assessed before initiating therapy and monitored periodically during treatment. In patients with renal artery stenosis, congestive heart failure, or volume depletion, ACE inhibitors can cause a rise in serum creatinine and blood urea nitrogen. Dosage reduction or discontinuation may be necessary. Hydrochlorothiazide should not be used in severe renal impairment.
- Hypotension: Symptomatic hypotension (low blood pressure) is possible, especially at the start of treatment, in patients who are volume-depleted (e.g., from diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting). Volume depletion should be corrected before starting Kinoprilam comp, or treatment should be initiated under close medical supervision.
- Potassium levels: Although the combination partially offsets the hypokalemic effect of hydrochlorothiazide, monitoring of serum potassium is still recommended, particularly in patients with renal impairment, diabetes, or those taking other medications that affect potassium levels.
- Cough: A persistent, non-productive (dry) cough has been reported with all ACE inhibitors and usually resolves after discontinuation. This should be considered in the differential diagnosis of cough in patients taking Kinoprilam comp. The incidence ranges from 5% to 35% depending on the population studied.
- Surgery and anesthesia: ACE inhibitors may enhance the hypotensive effects of certain anesthetic agents. Inform your surgeon and anesthesiologist that you are taking Kinoprilam comp before any planned surgery.
- Lithium: The combination of lithium and ACE inhibitors or diuretics increases the risk of lithium toxicity. Concomitant use is generally not recommended; if essential, serum lithium levels must be monitored closely.
- Diabetes: Both components may affect glucose metabolism. Hydrochlorothiazide can increase blood glucose levels and may require adjustment of diabetic medications. Quinapril may increase insulin sensitivity. Blood glucose should be monitored regularly in diabetic patients.
Pregnancy and Breastfeeding
Kinoprilam comp must not be used during pregnancy. ACE inhibitors cause serious fetal harm including renal failure, skull deformities, pulmonary hypoplasia, and death, particularly during the second and third trimesters. If you become pregnant while taking this medication, discontinue it immediately and contact your doctor. Women of childbearing potential should use effective contraception during treatment.
During the first trimester, limited epidemiological evidence has not shown a clear increased risk of malformation with ACE inhibitors; however, a small increase in risk cannot be excluded. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be switched to an alternative antihypertensive treatment with an established safety profile for use in pregnancy (such as methyldopa, labetalol, or nifedipine).
Both quinapril and hydrochlorothiazide are excreted in human breast milk. Hydrochlorothiazide in particular is known to suppress lactation at high doses. Because of the potential for serious adverse reactions in the breastfed infant, including electrolyte disturbances and potential effects on the developing kidney, Kinoprilam comp should not be used during breastfeeding. If treatment is essential, an alternative medication should be chosen that is compatible with breastfeeding, and the decision should be made in consultation with your doctor.
Driving and Operating Machinery
Kinoprilam comp may cause dizziness, lightheadedness, or fatigue, particularly at the start of treatment or when the dose is increased. These effects can impair your ability to drive or operate machinery. Patients should be advised not to drive or perform tasks requiring alertness until they know how this medication affects them individually. The risk of dizziness is increased by alcohol consumption, hot weather, prolonged standing, or exercise.
How Does Kinoprilam Comp Interact with Other Drugs?
Both quinapril and hydrochlorothiazide interact with a number of commonly used medications. Understanding these interactions is essential for safe use of Kinoprilam comp. The interactions can be broadly categorized into those related to the ACE inhibitor component (quinapril), those related to the thiazide diuretic component (hydrochlorothiazide), and those affecting both components. Below is a comprehensive overview of the most important drug interactions.
Major Interactions
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| Aliskiren | Dual RAAS blockade increases risk of hyperkalemia, hypotension, and acute kidney injury | Contraindicated in patients with diabetes or renal impairment (GFR <60) |
| Sacubitril/valsartan (Entresto) | Greatly increased risk of angioedema due to combined inhibition of neprilysin and ACE | Contraindicated. Allow 36-hour washout period between agents |
| Potassium supplements / K-sparing diuretics | Risk of life-threatening hyperkalemia; quinapril reduces aldosterone and potassium excretion | Avoid unless serum potassium is being closely monitored |
| Lithium | Both ACE inhibitors and thiazides reduce lithium excretion, risking lithium toxicity | Combination generally not recommended; if unavoidable, monitor lithium levels frequently |
| NSAIDs (ibuprofen, naproxen, diclofenac) | Reduced antihypertensive effect; increased risk of acute kidney injury and hyperkalemia | Use with caution, especially in elderly or volume-depleted patients; monitor renal function |
Moderate Interactions
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| Antidiabetic agents (insulin, metformin, sulfonylureas) | HCTZ may raise blood glucose; quinapril may increase insulin sensitivity | Monitor blood glucose; dose adjustment of antidiabetic drugs may be needed |
| Digoxin | HCTZ-induced hypokalemia or hypomagnesemia may increase risk of digoxin toxicity | Monitor electrolytes and digoxin levels; maintain normal potassium |
| Other antihypertensives (calcium channel blockers, beta-blockers) | Additive blood pressure-lowering effect; increased risk of hypotension | May be used together with appropriate monitoring; dose adjustment may be needed |
| Corticosteroids / ACTH | May intensify HCTZ-induced electrolyte depletion, especially hypokalemia | Monitor electrolytes when co-administered |
| Allopurinol | Increased risk of hypersensitivity reactions and leukopenia with ACE inhibitors | Use combination with caution; monitor blood counts |
| Alcohol, barbiturates, opioids | May potentiate orthostatic hypotension caused by HCTZ | Use with caution; advise patients about dizziness when standing |
Always carry a list of all your medications (including over-the-counter drugs, herbal supplements, and vitamins) and show it to every healthcare provider you see. This is especially important with Kinoprilam comp because both of its active ingredients interact with commonly used drugs. Pay particular attention to pain relievers (NSAIDs), potassium supplements, and salt substitutes (which often contain potassium chloride).
What Is the Correct Dosage of Kinoprilam Comp?
Kinoprilam comp should be used exactly as prescribed by your doctor. The fixed-dose combination tablet is intended for patients who require both quinapril and hydrochlorothiazide at the doses contained in the tablet. It is not appropriate for initial therapy in most patients; rather, it is used when blood pressure has not been adequately controlled with either component alone, or when patients are already stabilized on both drugs at equivalent doses given separately.
Adults
Standard Dosing
One tablet of Kinoprilam comp 10 mg/12.5 mg taken once daily, preferably in the morning. The tablet should be swallowed whole with a glass of water. It can be taken with or without food, although taking it at a consistent time each day is recommended. The blood pressure lowering effect is usually evident within 1–2 hours, with peak effect at approximately 2–6 hours and duration of approximately 24 hours, supporting once-daily dosing.
| Patient Group | Dose | Notes |
|---|---|---|
| Adults | 1 tablet (10/12.5 mg) once daily | Take in the morning; blood pressure control lasts approximately 24 hours |
| Elderly (≥65 years) | Start cautiously; standard dose if tolerated | May be more sensitive to hypotension and electrolyte changes; monitor closely |
| Mild-moderate renal impairment (CrCl 30–80 mL/min) | Titrate individual components first | Monitor renal function and electrolytes; dose adjustment may be required |
| Severe renal impairment (CrCl <30 mL/min) | Contraindicated | HCTZ is ineffective; use alternative antihypertensive agents |
| Hepatic impairment | Use with caution; contraindicated if severe | Thiazides can precipitate hepatic coma; monitor liver function |
Children and Adolescents
Kinoprilam comp is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of the quinapril/hydrochlorothiazide combination have not been established in pediatric patients. Hypertension in children requires specialized assessment and management by a pediatric cardiologist or nephrologist, and different medications with established pediatric safety data should be used.
Elderly Patients
Elderly patients may be more susceptible to the blood pressure-lowering effects of Kinoprilam comp, particularly if they are volume-depleted or have impaired renal function. Treatment should be initiated cautiously, with regular monitoring of blood pressure (including standing blood pressure to assess orthostatic hypotension), renal function, and serum electrolytes. The dose should be titrated on the individual components before switching to the fixed-dose combination. Clinical pharmacokinetic studies have shown that the apparent elimination half-life of quinaprilat is prolonged as creatinine clearance decreases. Dose adjustments based on renal function may be necessary.
Missed Dose
If you forget to take a dose of Kinoprilam comp, take it as soon as you remember on the same day. However, if it is nearly time for your next dose (e.g., you remember the following morning), skip the missed dose and continue with your normal schedule. Never take two tablets at the same time or take a double dose to compensate for a forgotten dose. Consistent daily dosing is important for maintaining steady blood pressure control; if you frequently forget doses, consider using a pill organizer, phone alarm, or other reminder system.
Overdose
In the event of overdose, the most likely clinical manifestations would be related to severe hypotension (dangerously low blood pressure), which can cause dizziness, fainting, or circulatory shock. Other potential effects include excessive diuresis leading to electrolyte depletion (especially low sodium and potassium), dehydration, metabolic alkalosis, and possibly acute kidney injury. Treatment of overdose is supportive and symptomatic. The patient should be placed in the supine position with legs elevated to improve venous return. Intravenous normal saline should be administered to expand intravascular volume. Quinaprilat is partially removable by hemodialysis. Serum electrolytes and renal function should be monitored closely. If you suspect an overdose, seek immediate medical attention or contact your local poison control center.
What Are the Side Effects of Kinoprilam Comp?
Like all medicines, Kinoprilam comp can cause side effects, although not everybody gets them. The side effects are primarily those known from the individual components, quinapril and hydrochlorothiazide. The frequency categories follow the international convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), and rare (<1/1,000). Understanding the side effect profile of each component helps you know what to expect and when to seek medical advice.
It is important to note that many patients tolerate Kinoprilam comp well, and the combination of a low-dose thiazide with an ACE inhibitor generally has a better side effect profile than higher doses of either drug alone. The 12.5 mg dose of hydrochlorothiazide is considered a low dose, which minimizes metabolic side effects while maintaining most of the antihypertensive benefit.
Very Common
Affects more than 1 in 10 patients
- Cough (dry, persistent, non-productive – due to quinapril/ACE inhibition; occurs in up to 35% of patients in some populations)
Common
Affects 1 in 10 to 1 in 100 patients
- Dizziness and lightheadedness (especially when standing up quickly)
- Headache
- Fatigue and weakness
- Nausea and gastrointestinal discomfort
- Increased urination (polyuria, from hydrochlorothiazide)
- Muscle cramps (from electrolyte changes)
- Upper respiratory tract infection symptoms
- Mild electrolyte disturbances (low potassium, low sodium, low magnesium)
- Elevated blood uric acid levels
- Mild increases in blood cholesterol and triglycerides
Uncommon
Affects 1 in 100 to 1 in 1,000 patients
- Angioedema (swelling of face, lips, tongue, or throat – seek immediate medical attention)
- Hypotension (low blood pressure), including orthostatic hypotension
- Skin rash, urticaria (hives), or pruritus (itching)
- Taste disturbances (dysgeusia)
- Elevated serum creatinine and blood urea nitrogen (impaired kidney function)
- Hyperkalemia (elevated potassium, especially in patients with renal impairment)
- Elevated blood glucose (may affect diabetes control)
- Palpitations and chest discomfort
- Diarrhea, abdominal pain, or vomiting
- Insomnia or drowsiness
- Photosensitivity (increased sun sensitivity, from hydrochlorothiazide)
Rare
Affects fewer than 1 in 1,000 patients
- Severe allergic reactions (anaphylaxis)
- Pancreatitis (inflammation of the pancreas)
- Hepatitis or jaundice (liver inflammation)
- Blood disorders: neutropenia, agranulocytosis, thrombocytopenia (more likely in patients with renal impairment or collagen vascular disease)
- Interstitial nephritis (kidney inflammation)
- Stevens-Johnson syndrome or toxic epidermal necrolysis (severe skin reactions, from HCTZ)
- Acute angle-closure glaucoma or acute myopia (from hydrochlorothiazide)
- Systemic lupus erythematosus exacerbation or activation (from HCTZ)
Contact emergency services or go to the nearest emergency department immediately if you experience: sudden swelling of the face, tongue, lips, or throat (angioedema); difficulty breathing or swallowing; severe skin reaction with blistering; signs of severe infection (high fever, sore throat, mouth ulcers); or severe abdominal pain with nausea and vomiting (possible pancreatitis). These are rare but potentially life-threatening side effects.
The ACE inhibitor-related cough is the most frequently reported side effect and deserves special attention. This cough is dry, persistent, and non-productive (no phlegm). It is caused by the accumulation of bradykinin and substance P in the lungs due to ACE inhibition. The cough typically appears within the first few months of treatment and resolves completely within 1–4 weeks after stopping the medication. The cough is more common in women and in patients of African or Asian descent. If the cough is intolerable, your doctor may switch you to an angiotensin receptor blocker (ARB) combined with a diuretic, which provides similar blood pressure control without the cough.
Regarding the metabolic effects of hydrochlorothiazide, the low dose of 12.5 mg used in Kinoprilam comp has been shown to have significantly fewer metabolic side effects compared with higher doses (25–50 mg). Studies have demonstrated that 12.5 mg HCTZ produces approximately 70–80% of the blood pressure reduction of 25 mg, with substantially less effect on glucose, lipids, and uric acid. Nevertheless, regular monitoring of these parameters is recommended, particularly in patients with pre-existing diabetes, dyslipidemia, or gout.
How Should You Store Kinoprilam Comp?
Proper storage of Kinoprilam comp is essential to ensure that the medication remains effective and safe throughout its shelf life. The film-coated tablets should be stored at room temperature, not exceeding 25°C (77°F). Keep the tablets in the original blister packaging or container to protect them from moisture and light, as hydrochlorothiazide can be sensitive to light degradation over extended periods.
Do not store Kinoprilam comp in the bathroom, near a kitchen sink, or in other damp, warm areas. Avoid exposing the tablets to direct sunlight or extreme temperatures (do not freeze). If you use a weekly pill organizer, only transfer the tablets for that week and keep the remaining tablets sealed in the original packaging.
Keep this and all medicines out of the reach and sight of children. A locked medicine cabinet or high shelf is recommended. Do not use the tablets after the expiry date stated on the blister or carton (the expiry date refers to the last day of that month). If you notice any visible changes in the appearance of the tablets (discoloration, crumbling, or unusual smell), do not take them and consult your pharmacist.
Do not dispose of unwanted medicines via household waste or wastewater. Return unused or expired tablets to your pharmacist for safe disposal according to local regulations. Proper disposal helps protect the environment and prevents accidental ingestion by children, pets, or others.
What Does Kinoprilam Comp Contain?
Active Ingredients
Each film-coated tablet of Kinoprilam comp contains:
- Quinapril hydrochloride equivalent to 10 mg quinapril – the ACE inhibitor component
- Hydrochlorothiazide 12.5 mg – the thiazide diuretic component
Excipients (Inactive Ingredients)
The tablet also contains various excipients (inactive ingredients) that serve pharmaceutical purposes such as binding, filling, coating, and ensuring proper tablet disintegration. Typical excipients in quinapril/HCTZ combination tablets include:
- Lactose monohydrate – filler/diluent (patients with lactose intolerance should be aware of this ingredient and discuss with their doctor)
- Magnesium carbonate – stabilizer
- Crospovidone – disintegrant
- Povidone – binder
- Magnesium stearate – lubricant
- Candelilla wax – coating agent
- Hypromellose (HPMC) – film-coating agent
- Titanium dioxide (E171) – coating colorant
- Iron oxide (E172) – coating colorant
The film coating gives the tablet its characteristic appearance and helps protect the active ingredients from moisture and light, while also making the tablet easier to swallow. The specific excipient list may vary slightly between manufacturers or country-specific formulations; always refer to the patient information leaflet included with your specific medication for the exact composition.
Kinoprilam comp contains lactose monohydrate as an excipient. If you have been told by your doctor that you have an intolerance to some sugars, discuss this with your doctor or pharmacist before taking this medicine. The amount of lactose per tablet is small, and most patients with mild lactose intolerance tolerate it without problems, but patients with rare hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
Frequently Asked Questions About Kinoprilam Comp
Kinoprilam comp is a combination medicine containing quinapril (an ACE inhibitor) and hydrochlorothiazide (a thiazide diuretic) used for the treatment of high blood pressure (hypertension) in adults. It is typically prescribed when blood pressure is not adequately controlled with quinapril or hydrochlorothiazide alone, or as a convenient alternative for patients already stabilized on both components given separately.
Take one Kinoprilam comp 10 mg/12.5 mg film-coated tablet once daily, preferably in the morning. The tablet can be taken with or without food. Swallow the tablet whole with a glass of water. Try to take it at the same time each day to maintain consistent blood levels. Do not stop taking the medication without consulting your doctor, even if you feel well, as hypertension often has no symptoms.
The most common side effects include dry cough (caused by the quinapril component, affecting up to 35% of patients in some populations), dizziness, headache, fatigue, and nausea. The hydrochlorothiazide component may cause increased urination, mild electrolyte changes, and slight elevations in blood sugar or uric acid. Most side effects are mild and may improve as your body adjusts. Contact your doctor if any side effects become severe or persistent.
No. Kinoprilam comp must not be used during pregnancy, especially during the second and third trimesters. ACE inhibitors such as quinapril can cause serious harm to the developing fetus, including reduced kidney function, low amniotic fluid (oligohydramnios), skull malformations, and fetal death. If you become pregnant while taking Kinoprilam comp, stop the medication immediately and contact your doctor. Women of childbearing potential should use effective contraception during treatment.
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one. If you frequently forget doses, consider setting a daily alarm or using a pill organizer to help you remember.
Alcohol should be consumed with caution while taking Kinoprilam comp. Alcohol can enhance the blood pressure-lowering effect of the medication, potentially leading to dizziness, lightheadedness, or fainting, especially when standing up. It is advisable to limit alcohol intake and be aware of how you respond to the combination. Discuss your alcohol consumption with your doctor.
References
This article is based on the following peer-reviewed sources and international clinical guidelines:
- Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. Journal of Hypertension. 2023;41(12):1874-2071.
- McEvoy JW, McCarthy S, Bruno JG, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal. 2024;45(38):3912-4018.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018;71(19):e127-e248.
- World Health Organization. Guideline for the pharmacological treatment of hypertension in adults. Geneva: WHO; 2021.
- ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic (ALLHAT). JAMA. 2002;288(23):2981-2997.
- European Medicines Agency. Summary of Product Characteristics: Quinapril/Hydrochlorothiazide combination products. EMA; 2024.
- U.S. Food and Drug Administration. Quinapril Hydrochloride and Hydrochlorothiazide Tablets Label. FDA; 2023.
- British National Formulary (BNF). Quinapril with hydrochlorothiazide. NICE Evidence Services; 2025.
- Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427.
- Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527-1535.
Medical Editorial Team
This article was written and reviewed by our team of medical professionals with expertise in cardiology, hypertension management, and clinical pharmacology.
Medical Content Team
Specialist physicians in internal medicine and cardiology with clinical and academic experience in hypertension management
Pharmacology Review
Clinical pharmacologists specializing in cardiovascular pharmacotherapy and drug interactions
Evidence Review
Systematic review of current ESC/ESH, AHA/ACC, and WHO hypertension guidelines and peer-reviewed literature
Accessibility Team
WCAG 2.2 AAA compliance verification and assistive technology testing
All content follows the iMedic Editorial Standards and is reviewed according to the GRADE evidence framework. No commercial funding or pharmaceutical company sponsorship.